MAXILUS
A Phase 3b, Open-label Study Evaluating the Efficacy and Safety of Luspatercept (BMS-986346/ACE-536) Initiated at Maximum Approved Dose in LR-MDS With IPSS-R Very Low-, Low-, or Intermediate-risk Who Require RBC Transfusions (MAXILUS)
More Information
- Trial Status
- Accepting patients
- Trial Phase
- Phase 3
- Enrollment
- 100 patients (estimated)
- Sponsors
- Bristol Myers Squibb
- Tags
- Erythroid Maturation Agent (EMA), Red Blood Cell Stimulant
- Trial Type
- Treatment
- Last Update
- 4 weeks ago
- SparkCures ID
- 1768
- NCT Identifier
- NCT06045689
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print a patient-friendly report to share with your patient.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.